Drug Profile

Alendronic acid effervescent - EffRx

Alternative Names: Alendronate effervescent; Alendronate sodium; Binosto; Buffered effervescent alendronate; EX-101; Steovess

Latest Information Update: 17 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator EffRx
Developer Abiogen Pharma; Adcock Ingram Pharmaceuticals; Ahn-Gook Pharmaceutical; Andrus; Ascendancy Healthcare; EffRx; Hikma Pharmaceuticals; Laboratorios Atral; Lacer; Mission Pharmacal
Class Alcohols; Antihypercalcaemics; Bisphosphonates; Butylamines; Calcium regulators; Osteoporosis therapies; Small molecules
Mechanism of Action Osteoclast inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Marketed Male osteoporosis; Osteoporosis; Postmenopausal osteoporosis

Most Recent Events

18 Dec 2024 Launched for Osteoporosis in Hong Kong (PO)
07 May 2024 Alendronic acid effervescent licensed to Pyridam Farma in Indonesia
06 Feb 2024 Alendronic acid effervescent licensed to Lupin in Vietnam and the Philippines

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com